Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype

Ilaria Callegari, C. Gemelli, A. Geroldi, F. Veneri, P. Mandich, M. D’Antonio, D. Pareyson, M. E. Shy, A. Schenone, V. Prada, M. Grandis

Research output: Contribution to journalArticle

Abstract

Mutations of myelin protein zero gene (MPZ) are found in 5% of Charcot–Marie–Tooth patients. In 2004, Shy et al. identified two main phenotypes associated with them: an early-onset subtype with mainly demyelinating features and a late-onset subgroup with prominent axonal impairment. We evaluated whether novel MPZ mutations described in literature during the last 14 years could still fit with this classification. We collected and revised reports of 69 novel MPZ mutations. Almost 90% of them could be alternatively classified as responsible for: (a) an early-onset phenotype, with first limitations starting before 3 years (2.5 ± 0.50 years), motor milestones delays, frequently severe course and upper limb MNCVs below 15 m/s; (b) late-onset neuropathy, with mean age of onset of 42.8 ± 1.5 years and mean upper limbs motor nerve conduction velocities (MNCVs) of 47.2 ± 1.4 m/s; (c) a phenotype more similar to typical CMT1A neuropathy, with onset during the 2nd decade, MNCV in the range of 15–30 m/s and slowly progressive course. The present work confirms that P0-related neuropathies may be separated into two main distinct phenotypes, while a third, relatively small, group comprehend patients carrying MPZ mutations and a childhood-onset disease, substantiating the subdivision into three groups proposed by Sanmaneechai et al. (Brain 138:3180–3192, 2015). Interestingly, during the last years, an increasing number of novel MPZ mutations causing a late-onset phenotype has been described, highlighting the clinical relevance of late-onset P0 neuropathies. Since the family history for neuropathy is often uncertain, due to the late disease onset, the number of patients carrying this genotype is probably underestimated.

Original languageEnglish
JournalJournal of Neurology
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Myelin P0 Protein
Neural Conduction
Phenotype
Mutation
Genes
Upper Extremity
Age of Onset
Genotype
Brain

Keywords

  • Charcot–Marie–Tooth
  • Genotype–phenotype correlation
  • Myelin protein zero
  • Phenotype classification

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype. / Callegari, Ilaria; Gemelli, C.; Geroldi, A.; Veneri, F.; Mandich, P.; D’Antonio, M.; Pareyson, D.; Shy, M. E.; Schenone, A.; Prada, V.; Grandis, M.

In: Journal of Neurology, 01.01.2019.

Research output: Contribution to journalArticle

@article{c7209eb5ed8d4141943ec58cbbb0ece9,
title = "Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype",
abstract = "Mutations of myelin protein zero gene (MPZ) are found in 5{\%} of Charcot–Marie–Tooth patients. In 2004, Shy et al. identified two main phenotypes associated with them: an early-onset subtype with mainly demyelinating features and a late-onset subgroup with prominent axonal impairment. We evaluated whether novel MPZ mutations described in literature during the last 14 years could still fit with this classification. We collected and revised reports of 69 novel MPZ mutations. Almost 90{\%} of them could be alternatively classified as responsible for: (a) an early-onset phenotype, with first limitations starting before 3 years (2.5 ± 0.50 years), motor milestones delays, frequently severe course and upper limb MNCVs below 15 m/s; (b) late-onset neuropathy, with mean age of onset of 42.8 ± 1.5 years and mean upper limbs motor nerve conduction velocities (MNCVs) of 47.2 ± 1.4 m/s; (c) a phenotype more similar to typical CMT1A neuropathy, with onset during the 2nd decade, MNCV in the range of 15–30 m/s and slowly progressive course. The present work confirms that P0-related neuropathies may be separated into two main distinct phenotypes, while a third, relatively small, group comprehend patients carrying MPZ mutations and a childhood-onset disease, substantiating the subdivision into three groups proposed by Sanmaneechai et al. (Brain 138:3180–3192, 2015). Interestingly, during the last years, an increasing number of novel MPZ mutations causing a late-onset phenotype has been described, highlighting the clinical relevance of late-onset P0 neuropathies. Since the family history for neuropathy is often uncertain, due to the late disease onset, the number of patients carrying this genotype is probably underestimated.",
keywords = "Charcot–Marie–Tooth, Genotype–phenotype correlation, Myelin protein zero, Phenotype classification",
author = "Ilaria Callegari and C. Gemelli and A. Geroldi and F. Veneri and P. Mandich and M. D’Antonio and D. Pareyson and Shy, {M. E.} and A. Schenone and V. Prada and M. Grandis",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00415-019-09453-3",
language = "English",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",

}

TY - JOUR

T1 - Mutation update for myelin protein zero-related neuropathies and the increasing role of variants causing a late-onset phenotype

AU - Callegari, Ilaria

AU - Gemelli, C.

AU - Geroldi, A.

AU - Veneri, F.

AU - Mandich, P.

AU - D’Antonio, M.

AU - Pareyson, D.

AU - Shy, M. E.

AU - Schenone, A.

AU - Prada, V.

AU - Grandis, M.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Mutations of myelin protein zero gene (MPZ) are found in 5% of Charcot–Marie–Tooth patients. In 2004, Shy et al. identified two main phenotypes associated with them: an early-onset subtype with mainly demyelinating features and a late-onset subgroup with prominent axonal impairment. We evaluated whether novel MPZ mutations described in literature during the last 14 years could still fit with this classification. We collected and revised reports of 69 novel MPZ mutations. Almost 90% of them could be alternatively classified as responsible for: (a) an early-onset phenotype, with first limitations starting before 3 years (2.5 ± 0.50 years), motor milestones delays, frequently severe course and upper limb MNCVs below 15 m/s; (b) late-onset neuropathy, with mean age of onset of 42.8 ± 1.5 years and mean upper limbs motor nerve conduction velocities (MNCVs) of 47.2 ± 1.4 m/s; (c) a phenotype more similar to typical CMT1A neuropathy, with onset during the 2nd decade, MNCV in the range of 15–30 m/s and slowly progressive course. The present work confirms that P0-related neuropathies may be separated into two main distinct phenotypes, while a third, relatively small, group comprehend patients carrying MPZ mutations and a childhood-onset disease, substantiating the subdivision into three groups proposed by Sanmaneechai et al. (Brain 138:3180–3192, 2015). Interestingly, during the last years, an increasing number of novel MPZ mutations causing a late-onset phenotype has been described, highlighting the clinical relevance of late-onset P0 neuropathies. Since the family history for neuropathy is often uncertain, due to the late disease onset, the number of patients carrying this genotype is probably underestimated.

AB - Mutations of myelin protein zero gene (MPZ) are found in 5% of Charcot–Marie–Tooth patients. In 2004, Shy et al. identified two main phenotypes associated with them: an early-onset subtype with mainly demyelinating features and a late-onset subgroup with prominent axonal impairment. We evaluated whether novel MPZ mutations described in literature during the last 14 years could still fit with this classification. We collected and revised reports of 69 novel MPZ mutations. Almost 90% of them could be alternatively classified as responsible for: (a) an early-onset phenotype, with first limitations starting before 3 years (2.5 ± 0.50 years), motor milestones delays, frequently severe course and upper limb MNCVs below 15 m/s; (b) late-onset neuropathy, with mean age of onset of 42.8 ± 1.5 years and mean upper limbs motor nerve conduction velocities (MNCVs) of 47.2 ± 1.4 m/s; (c) a phenotype more similar to typical CMT1A neuropathy, with onset during the 2nd decade, MNCV in the range of 15–30 m/s and slowly progressive course. The present work confirms that P0-related neuropathies may be separated into two main distinct phenotypes, while a third, relatively small, group comprehend patients carrying MPZ mutations and a childhood-onset disease, substantiating the subdivision into three groups proposed by Sanmaneechai et al. (Brain 138:3180–3192, 2015). Interestingly, during the last years, an increasing number of novel MPZ mutations causing a late-onset phenotype has been described, highlighting the clinical relevance of late-onset P0 neuropathies. Since the family history for neuropathy is often uncertain, due to the late disease onset, the number of patients carrying this genotype is probably underestimated.

KW - Charcot–Marie–Tooth

KW - Genotype–phenotype correlation

KW - Myelin protein zero

KW - Phenotype classification

UR - http://www.scopus.com/inward/record.url?scp=85068879490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068879490&partnerID=8YFLogxK

U2 - 10.1007/s00415-019-09453-3

DO - 10.1007/s00415-019-09453-3

M3 - Article

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

ER -